CD28 and prostate carcinoma: 28ζ CAR bearing this modification outperformed BBζ CAR against prostate cancer [167], suggesting that excessive CD28-derived proximal signaling limited CAR T cell persistence, but adequate CD28 signaling could be a better option compared to 4-1BB in specific cases.